Symbols / IGC $0.28 -1.17%
IGC Chart
About
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 26.58M |
| Enterprise Value | 24.99M | Income | -6.45M | Sales | 1.11M |
| Book/sh | 0.09 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 70 | IPO | — |
| P/E | — | Forward P/E | -3.11 | PEG | — |
| P/S | 24.03 | P/B | 3.18 | P/C | — |
| EV/EBITDA | -3.32 | EV/Sales | 22.60 | Quick Ratio | 0.79 |
| Current Ratio | 1.32 | Debt/Eq | 1.80 | LT Debt/Eq | — |
| EPS (ttm) | -0.07 | EPS next Y | -0.09 | EPS Growth | — |
| Revenue Growth | -53.60% | Earnings | 2025-11-14 16:00 | ROA | -50.31% |
| ROE | -83.34% | ROIC | — | Gross Margin | 46.20% |
| Oper. Margin | -15.18% | Profit Margin | 0.00% | Shs Outstand | 95.04M |
| Shs Float | 84.64M | Short Float | 0.93% | Short Ratio | 1.92 |
| Short Interest | — | 52W High | 0.50 | 52W Low | 0.24 |
| Beta | 0.30 | Avg Volume | 488.36K | Volume | 164.61K |
| Target Price | $4.00 | Recom | None | Prev Close | $0.28 |
| Price | $0.28 | Change | -1.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$0.28
Latest analyst target
3. DCF / Fair value
$-0.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.28
Low
$3.00
High
$5.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-12-09 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-08-26 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-03-06 | reit | Alliance Global Partners | Buy → Buy | $4 |
| 2025-02-24 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-12-05 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-09-03 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-07-29 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-07-17 | init | Alliance Global Partners | — → Buy | $4 |
| 2024-06-21 | reit | Ascendiant Capital | Buy → Buy | $3 |
News
RSS: Latest IGC news- IGC Stock Price, Quote & Chart | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill Fri, 13 Mar 2026 07
- Analyst lifts IGC Pharma price target to $5 in new research note - Stock Titan ue, 24 Feb 2026 08
- New Analyst Forecast: $IGC Given $5 Price Target | IGC Stock News - Quiver Quantitative Mon, 23 Feb 2026 08
- IGC Pharma Secures ~$526K in Financing, Including Default-Convertible Note With Vanquish - TradingView hu, 12 Mar 2026 10
- Would You Still Hold IGC Pharma Stock If It Fell Another 30%? - Trefis Sat, 20 Dec 2025 08
- IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance Fri, 14 Nov 2025 08
- IGC Pharma Secures New Debt Financing for Liquidity - TipRanks hu, 12 Mar 2026 11
- All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy - Nasdaq Fri, 24 Oct 2025 07
- Alzheimer’s agitation trial passes 70% enrollment milestone - Stock Titan Mon, 02 Feb 2026 08
- IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - ACCESS Newswire ue, 17 Feb 2026 08
- IGC Pharma (IGC): Ascendiant Capital Raises Price Target to $4.7 - GuruFocus ue, 09 Dec 2025 08
- IGC: Carryover stocks aided by record grains output - World-Grain.com hu, 15 Jan 2026 08
- IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." - Yahoo Finance Wed, 27 Aug 2025 07
- Inside IGC Pharma’s AI push to clean up Alzheimer’s data - Stock Titan hu, 26 Feb 2026 08
- IGC: Bumper harvests boost global grain stocks - World-Grain.com hu, 20 Nov 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | — | — | MUKUNDA RAM | Chief Executive Officer | — | 2026-02-03 00:00:00 | I | nan |
| 1 | 100000 | — | — | PRINS RICHARD K | Director | — | 2026-01-16 00:00:00 | D | nan |
| 2 | 100000 | — | Stock Gift at price 0.00 per share. | MUKUNDA RAM | Chief Executive Officer | — | 2025-10-17 00:00:00 | D | — |
| 3 | 50000 | — | Stock Gift at price 0.00 per share. | GRIMALDI CLAUDIA | Officer and Director | — | 2025-10-17 00:00:00 | D | — |
| 4 | 566666 | — | — | MUKUNDA RAM | Chief Executive Officer | — | 2025-03-31 00:00:00 | D | nan |
| 5 | 228333 | — | — | PRINS RICHARD K | Director | — | 2025-03-31 00:00:00 | D | nan |
| 6 | 158333 | — | — | GRIMALDI CLAUDIA | Director | — | 2025-03-31 00:00:00 | D | nan |
| 7 | 163333 | — | — | MORAN JAMES P | Director | — | 2025-03-31 00:00:00 | D | nan |
| 8 | 588235 | — | Purchase at price 0.34 per share. | MORAN JAMES P | Director | — | 2024-09-25 00:00:00 | I | 200000.0 |
| 9 | 200000 | — | Stock Gift at price 0.00 per share. | PRINS RICHARD K | Director | — | 2024-08-12 00:00:00 | D | — |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.83M | -5.82M | -10.91M | -14.73M |
| TotalUnusualItems | 0.00 | -3.35M | 0.00 | -49.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -3.35M | 0.00 | -49.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.12M | -13.00M | -11.51M | -15.02M |
| ReconciledDepreciation | 618.00K | 637.00K | 657.00K | 651.00K |
| ReconciledCostOfRevenue | 652.00K | 612.00K | 469.00K | 203.00K |
| EBITDA | -6.83M | -9.16M | -10.91M | -14.78M |
| EBIT | -7.45M | -9.80M | -11.57M | -15.43M |
| NormalizedIncome | -7.12M | -9.65M | -11.51M | -14.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.12M | -13.00M | -11.51M | -15.02M |
| TotalExpenses | 8.72M | 11.14M | 12.48M | 15.82M |
| TotalOperatingIncomeAsReported | -7.45M | -9.80M | -11.57M | -15.43M |
| DilutedAverageShares | 76.52M | 58.84M | 52.58M | 49.99M |
| BasicAverageShares | 76.52M | 58.84M | 52.58M | 49.99M |
| DilutedEPS | -0.09 | -0.22 | -0.22 | -0.30 |
| BasicEPS | -0.09 | -0.22 | -0.22 | -0.30 |
| DilutedNIAvailtoComStockholders | -7.12M | -13.00M | -11.51M | -15.02M |
| NetIncomeCommonStockholders | -7.12M | -13.00M | -11.51M | -15.02M |
| NetIncome | -7.12M | -13.00M | -11.51M | -15.02M |
| NetIncomeIncludingNoncontrollingInterests | -7.12M | -13.00M | -11.51M | -15.02M |
| NetIncomeContinuousOperations | -7.12M | -13.00M | -11.51M | -15.02M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -7.12M | -13.00M | -11.51M | -15.02M |
| OtherIncomeExpense | 325.00K | -3.20M | 65.00K | 412.00K |
| OtherNonOperatingIncomeExpenses | 325.00K | 143.00K | 65.00K | 461.00K |
| SpecialIncomeCharges | 0.00 | -3.35M | 0.00 | -49.00K |
| WriteOff | 0.00 | 49.00K | 169.00K | |
| ImpairmentOfCapitalAssets | 0.00 | 3.35M | 0.00 | |
| OperatingIncome | -7.45M | -9.80M | -11.57M | -15.43M |
| OperatingExpense | 8.06M | 10.53M | 12.01M | 15.62M |
| ResearchAndDevelopment | 3.65M | 3.77M | 3.46M | 2.33M |
| SellingGeneralAndAdministration | 4.41M | 6.76M | 8.55M | 13.29M |
| GrossProfit | 619.00K | 733.00K | 442.00K | 194.00K |
| CostOfRevenue | 652.00K | 612.00K | 469.00K | 203.00K |
| TotalRevenue | 1.27M | 1.34M | 911.00K | 397.00K |
| OperatingRevenue | 1.27M | 1.18M | 911.00K | 397.00K |
| Line Item | 2024-03-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 80.88M | 66.69M | 53.08M | 51.05M |
| ShareIssued | 80.88M | 66.69M | 53.08M | 51.05M |
| TotalDebt | 238.00K | 345.00K | 481.00K | 608.00K |
| TangibleBookValue | 4.48M | 5.71M | 13.74M | 22.98M |
| InvestedCapital | 6.46M | 7.46M | 15.05M | 24.04M |
| WorkingCapital | 639.00K | 1.36M | 4.57M | 12.67M |
| NetTangibleAssets | 4.48M | 5.71M | 13.74M | 22.98M |
| CapitalLeaseObligations | 104.00K | 208.00K | 340.00K | 464.00K |
| CommonStockEquity | 6.33M | 7.32M | 14.91M | 23.89M |
| TotalCapitalization | 6.46M | 7.46M | 15.05M | 24.04M |
| TotalEquityGrossMinorityInterest | 6.33M | 7.32M | 14.91M | 23.89M |
| StockholdersEquity | 6.33M | 7.32M | 14.91M | 23.89M |
| GainsLossesNotAffectingRetainedEarnings | -3.50M | -3.42M | -3.39M | -2.97M |
| OtherEquityAdjustments | -3.50M | -3.42M | -3.39M | -2.97M |
| RetainedEarnings | -120.74M | -113.67M | -100.67M | -89.16M |
| CapitalStock | 130.57M | 124.41M | 118.97M | 116.02M |
| CommonStock | 130.57M | 124.41M | 118.97M | 116.02M |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 2.42M | 2.58M | 2.27M | 2.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 160.00K | 241.00K | 369.00K | 501.00K |
| LongTermDebtAndCapitalLeaseObligation | 144.00K | 221.00K | 348.00K | 485.00K |
| LongTermCapitalLeaseObligation | 10.00K | 84.00K | 207.00K | 341.00K |
| LongTermDebt | 134.00K | 137.00K | 141.00K | 144.00K |
| LongTermProvisions | 16.00K | 20.00K | 21.00K | 16.00K |
| CurrentLiabilities | 2.26M | 2.34M | 1.90M | 2.44M |
| OtherCurrentLiabilities | 1.00M | 419.00K | 358.00K | 180.00K |
| CurrentDebtAndCapitalLeaseObligation | 94.00K | 124.00K | 133.00K | 123.00K |
| CurrentCapitalLeaseObligation | 94.00K | 124.00K | 133.00K | 123.00K |
| CurrentDebt | 3.00K | 304.00K | ||
| OtherCurrentBorrowings | 3.00K | 304.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 160.00K | 816.00K | 619.00K | 1.05M |
| CurrentProvisions | 117.00K | 208.00K | 258.00K | 103.00K |
| PayablesAndAccruedExpenses | 883.00K | 773.00K | 530.00K | 981.00K |
| Payables | 883.00K | 773.00K | 530.00K | 981.00K |
| AccountsPayable | 883.00K | 773.00K | 530.00K | 981.00K |
| TotalAssets | 8.75M | 9.90M | 17.18M | 26.83M |
| TotalNonCurrentAssets | 5.85M | 6.20M | 10.71M | 11.72M |
| NonCurrentPrepaidAssets | 1.00K | 2.00K | 52.00K | 569.00K |
| NonCurrentAccountsReceivable | 680.00K | 686.00K | 951.00K | 368.00K |
| InvestmentsAndAdvances | 0.00 | 12.00K | ||
| OtherInvestments | 0.00 | 12.00K | ||
| GoodwillAndOtherIntangibleAssets | 1.85M | 1.62M | 1.17M | 917.00K |
| OtherIntangibleAssets | 1.85M | 1.62M | 1.17M | 917.00K |
| NetPPE | 3.32M | 3.89M | 8.54M | 9.87M |
| AccumulatedDepreciation | -2.69M | -2.44M | -1.94M | -3.22M |
| GrossPPE | 6.01M | 6.33M | 10.47M | 13.09M |
| ConstructionInProgress | 0.00 | 0.00 | 108.00K | 50.00K |
| OtherProperties | 98.00K | 198.00K | 326.00K | 450.00K |
| MachineryFurnitureEquipment | 3.57M | 3.83M | 3.75M | 5.28M |
| BuildingsAndImprovements | 2.34M | 2.30M | 2.30M | 2.81M |
| LandAndImprovements | 0.00 | 4.10M | 4.44M | 4.61M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.90M | 3.71M | 6.47M | 15.11M |
| OtherCurrentAssets | 342.00K | 115.00K | 262.00K | 336.00K |
| AssetsHeldForSaleCurrent | 702.00K | 720.00K | 0.00 | |
| PrepaidAssets | 10.00K | 41.00K | 72.00K | 170.00K |
| Inventory | 1.36M | 1.54M | 2.65M | 3.55M |
| FinishedGoods | 256.00K | 441.00K | 533.00K | 717.00K |
| WorkInProcess | 0.00 | 18.00K | 584.00K | 2.20M |
| RawMaterials | 1.10M | 1.10M | 2.10M | 2.25M |
| Receivables | 77.00K | 91.00K | 131.00K | 597.00K |
| OtherReceivables | 43.00K | 52.00K | 24.00K | 472.00K |
| AccountsReceivable | 34.00K | 39.00K | 107.00K | 125.00K |
| AllowanceForDoubtfulAccountsReceivable | -12.00K | -24.00K | -17.00K | -93.00K |
| GrossAccountsReceivable | 46.00K | 63.00K | 124.00K | 218.00K |
| CashCashEquivalentsAndShortTermInvestments | 405.00K | 1.20M | 3.35M | 10.46M |
| OtherShortTermInvestments | 0.00 | 154.00K | 0.00 | 80.00K |
| CashAndCashEquivalents | 405.00K | 1.20M | 3.20M | 10.46M |
| CashEquivalents | 37.00K | 286.00K | 2.04M | |
| CashFinancial | 368.00K | 912.00K | 1.16M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.28M | -5.71M | -7.67M | -8.23M |
| RepaymentOfDebt | -3.00K | -3.00K | -3.00K | -3.00K |
| IssuanceOfDebt | 580.00K | |||
| IssuanceOfCapitalStock | 4.45M | 3.53M | 103.00K | 4.14M |
| CapitalExpenditure | -482.00K | -515.00K | -619.00K | -771.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 405.00K | 1.20M | 3.20M | 10.46M |
| BeginningCashPosition | 1.20M | 3.20M | 10.46M | 14.55M |
| EffectOfExchangeRateChanges | -7.00K | -6.00K | -82.00K | -26.00K |
| ChangesInCash | -786.00K | -1.99M | -7.18M | -4.06M |
| FinancingCashFlow | 4.45M | 3.52M | 100.00K | 4.14M |
| CashFlowFromContinuingFinancingActivities | 4.45M | 3.52M | 100.00K | 4.14M |
| NetCommonStockIssuance | 4.45M | 3.53M | 103.00K | 4.14M |
| CommonStockIssuance | 4.45M | 3.53M | 103.00K | 4.14M |
| NetIssuancePaymentsOfDebt | -3.00K | -3.00K | -3.00K | -3.00K |
| NetLongTermDebtIssuance | -3.00K | -3.00K | -3.00K | -3.00K |
| LongTermDebtPayments | -3.00K | -3.00K | -3.00K | -3.00K |
| LongTermDebtIssuance | 580.00K | |||
| InvestingCashFlow | -442.00K | -317.00K | -235.00K | -742.00K |
| CashFlowFromContinuingInvestingActivities | -442.00K | -317.00K | -235.00K | -742.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 154.00K | -154.00K | 0.00 |
| SaleOfInvestment | 0.00 | 5.13M | ||
| PurchaseOfInvestment | -154.00K | 0.00 | -149.00K | |
| NetIntangiblesPurchaseAndSale | -370.00K | -377.00K | -309.00K | -535.00K |
| PurchaseOfIntangibles | -370.00K | -377.00K | -309.00K | -535.00K |
| NetPPEPurchaseAndSale | -72.00K | -94.00K | 228.00K | -207.00K |
| SaleOfPPE | 40.00K | 44.00K | 538.00K | 29.00K |
| PurchaseOfPPE | -112.00K | -138.00K | -310.00K | -236.00K |
| OperatingCashFlow | -4.79M | -5.20M | -7.05M | -7.46M |
| CashFlowFromContinuingOperatingActivities | -4.79M | -5.20M | -7.05M | -7.46M |
| ChangeInWorkingCapital | -72.00K | 1.89M | 794.00K | 2.54M |
| ChangeInOtherWorkingCapital | 93.00K | |||
| ChangeInOtherCurrentLiabilities | -74.00K | -123.00K | -134.00K | -64.00K |
| ChangeInOtherCurrentAssets | 107.00K | 444.00K | -26.00K | -296.00K |
| ChangeInPayablesAndAccruedExpense | -90.00K | 440.00K | -539.00K | 375.00K |
| ChangeInAccruedExpense | -196.00K | 197.00K | -88.00K | -129.00K |
| ChangeInPayable | 106.00K | 243.00K | -451.00K | 504.00K |
| ChangeInAccountPayable | 106.00K | 243.00K | -451.00K | 504.00K |
| ChangeInPrepaidAssets | -187.00K | 150.00K | 591.00K | 541.00K |
| ChangeInInventory | 180.00K | 1.01M | 897.00K | 1.93M |
| ChangeInReceivables | -8.00K | -25.00K | 5.00K | 50.00K |
| ChangesInAccountReceivables | -8.00K | -25.00K | 5.00K | 50.00K |
| OtherNonCashItems | -430.00K | |||
| StockBasedCompensation | 1.64M | 1.77M | 2.84M | 2.20M |
| ProvisionandWriteOffofAssets | 13.00K | 93.00K | 126.00K | 1.72M |
| AssetImpairmentCharge | 152.00K | 3.45M | 0.00 | 882.00K |
| DepreciationAmortizationDepletion | 618.00K | 637.00K | 657.00K | 651.00K |
| DepreciationAndAmortization | 618.00K | 637.00K | 657.00K | 651.00K |
| AmortizationCashFlow | 74.00K | |||
| AmortizationOfIntangibles | 74.00K | |||
| Depreciation | 563.00K | |||
| OperatingGainsLosses | -25.00K | -44.00K | 39.00K | -430.00K |
| GainLossOnSaleOfPPE | -25.00K | -44.00K | 39.00K | 0.00 |
| NetIncomeFromContinuingOperations | -7.12M | -13.00M | -11.51M | -15.02M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IGC
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|